A1M Pharma AB has changed its name to Guard Therapeutics International AB
A1M Pharma holds three granted international patent families. Additional patent applications are pending.
Taken together, these patents and patent applications cover the product as well as the medical use of ROSgard (and similar drug candidates) in the treatment of kidney damage and various other medical conditions associated with increased oxidative stress.
*approved in at least one major region